BBC Sounds, music, radio podcasts.

Their company's success helped build a nation.

The company is such a big part of Korea's economy.

But who are the family behind one of the world's tech giants?

They often say, look, we built the nation.

And without us, South Korea as it exists today,

would simply not be here. Inheritance, Samsung explores the real-life dramas of the Lee family

and their company. They are the equivalent of royalty. Listen first on BBC Sounds.

You know, I think it's underappreciated in some countries how desperate this crisis is

already. The bacterium we target is these carbapenum resistant introbacteracy. It's a very rare

infection in the UK. But if you go to Greece, they have in their ICU's a pathogen known as

Klebsiella. Already 90% of Klebsiella in those ICUs are resistant to carbopenoms, and carbopenoms are the last line of antibiotic defence. So these are patients in intensive care units with serious infections with no antibiotic options. 10 years ago, Greece didn't have CRE, so it can happen very quickly, and we're seeing this global spread. So there is a need to act early

in advance of the crisis really being an enormous medical and, of course, national problem.

That is, I'm afraid, not news. It's from an interview 11 years ago,

since when the medical crisis due to Carbopenum-resistant klebsiella has only grown worse. In 2017,

the World Health Organization put the bugs into the top critical category of priority pathogens

needing new antibiotics. My interview with Kenneth Hillen two years earlier was relevant. He was

the CEO of a company that was in

the final stages of testing the kind of new antibiotic the world needed. His company, a caogen,

was a small startup, hoping to fill a space vacated by the big drugs multinationals. I think the

challenge is that the economic model for antibiotics is fundamentally

broken. And the reason for that is, first, that for most infections, today's antibiotics can be

...